Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802230 · ClinicalTrials.gov registry record · Phase 4
Pharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure
A Phase 4 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT00802230 is a Phase 4 study that has completed, run by University of Utah. The registered enrollment target is 25 participants.
The verdict
NCT00802230, a Phase 4 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
Metoprolol succinate is a beta1-selective beta-blocker, becoming non-selective at higher doses, while carvedilol is non-selective. We examined whether metoprolol remained beta1-selective compared to carvedilol during dose up-titration in Class C heart failure (HF) Beta-blocker naïve patients. METHODS: Twenty-five NYHA FC II-III HF patients were randomized to carvedilol or metoprolol. Patients were studied at baseline and after 2 weeks of up-titration (metoprolol at 25, 50, 100, and 200 mg daily; carvedilol IR at 3.125, 6.25, 12.5, 25 mg and 50mg twice daily). Beta2- blockade was determined by an infusion of terbutaline at 6 mg/kg over 1 hour. Glucose and potassium levels were serially measured at baseline, every 15 minutes for the 1st hour and 30 minutes for 2nd hour post-infusion. The median area under the curve (AUC) for glucose and potassium changes were calculated.
Interventions
- DRUG Terbutaline Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-09 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00802230
The ClinicalTrials.gov registry entry for NCT00802230 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Terbutaline Infusion is the first listed.
NCT00802230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00802230 about?
NCT00802230 is a clinical study titled "Pharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure". Metoprolol succinate is a beta1-selective beta-blocker, becoming non-selective at higher doses, while carvedilol is non-selective. We examined whether metoprolol remained beta1-selective compared to carvedilol during dose up-titration in Class C heart failure (HF) Beta-blocker naïve patients. METHO...
What is the current status of trial NCT00802230?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2002-09. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00802230?
The interventions under investigation include: Terbutaline Infusion (DRUG).
Who is sponsoring clinical trial NCT00802230?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.